Modality
Peptide
MOA
PI3Ki
Target
GPRC5D
Pathway
mTOR
Fabry
Development Pipeline
Preclinical
~Aug 2018
→ ~Nov 2019
Phase 1
~Feb 2020
→ ~May 2021
Phase 2
~Aug 2021
→ ~Nov 2022
Phase 3
Feb 2023
Phase 3Current
NCT05900099
704 pts·Fabry
2023-02→TBD·Recruiting
704 total pts1 indication
NDA/BLA
Approved
CompletedCurrentUpcoming
Trial Timeline
P3
Recruit…
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05900099 | Phase 3 | Fabry | Recruiting | 704 | UPCR |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Tiramavacamten | Roche | Preclinical | SGLT2 | |
| Pexatenlimab | Novartis | Phase 1/2 | GPRC5D | |
| NVS-5126 | Novartis | Phase 3 | SHP2 | |
| Ribotuximab | Merck & Co | Phase 2 | GPRC5D | |
| Voxacilimab | AstraZeneca | Phase 1/2 | GLP-1R | |
| BMY-9931 | Bristol-Myers Squibb | Phase 1 | GPRC5D | |
| Capifutibatinib | Sanofi | Approved | PRMT5 | |
| NVO-7877 | Novo Nordisk | Preclinical | GPRC5D | |
| Rimatenlimab | Novo Nordisk | Phase 2/3 | SGLT2 | |
| AMG-9654 | Amgen | Phase 2 | GPRC5D |